G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Operating Margin
Genovis AB

18.3%
Current
24%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.3%
=
Operating Profit
23.2m
/
Revenue
127m

Operating Margin Across Competitors

Country SE
Market Cap 1.8B SEK
Operating Margin
18%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.3B USD
Operating Margin
17%
Country US
Market Cap 170.3B USD
Operating Margin
21%
Country KR
Market Cap 66.5T KRW
Operating Margin
31%
Country CH
Market Cap 37.6B CHF
Operating Margin
13%
Country US
Market Cap 38.5B USD
Operating Margin
25%
Country US
Market Cap 36.7B USD
Operating Margin
14%
Country US
Market Cap 26.4B USD
Operating Margin
28%
Country US
Market Cap 23B USD
Operating Margin
20%
Country US
Market Cap 22.3B USD
Operating Margin
8%
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.3%
=
Operating Profit
23.2m
/
Revenue
127m
What is the Operating Margin of Genovis AB?

Based on Genovis AB's most recent financial statements, the company has Operating Margin of 18.3%.